

Resource Summary Report

Generated by [NIF](#) on Sep 9, 2026

ONS-76

RRID:CVCL_1624

Type: Cell Line

Proper Citation

RRID:CVCL_1624

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1624

Proper Citation: RRID:CVCL_1624

Description: Cell line ONS-76 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Medulloblastoma, SHH-activated, TP53-wildtype

Defining Citation: [PMID:1992917](#), [PMID:2504489](#), [PMID:2818910](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:22951319](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:27498314](#), [PMID:27812533](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31346954](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: ONS-76

Synonyms: ONS76, Osaka Neurological Surgery-76

Cross References: CLO:CLO_0009900, EFO:EFO_0022571, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BCRJ:0294, BioGRID_ORCS_Cell_line:513, BioSample:SAMN03470886, BioSample:SAMN10988186, cancercellines:CVCL_1624, Cell_Model_Passport:SIDM00567, ChEMBL-Cells:ChEMBL3308540, ChEMBL-Targets:ChEMBL2366068, Cosmic:909248, Cosmic:1995603, Cosmic-CLP:909248, DepMap:ACH-000776, EGA:EGAS00001000978, FANTOM5_SSTAR:10759-110E3, GDSC:909248, GEO:GSM887477, GEO:GSM888558,

GEO:GSM919364, GEO:GSM1670306, IARC_TP53:21602, JCRB:IFO50355, LiGeA:CCLE_428, LINCS_LDP:LCL-1578, PharmacDB:ONS76_1201_2019, PRIDE:PXD030304, Progenetix:CVCL_1624, PubChem_Cell_line:CVCL_1624, Wikidata:Q54936426

ID: CVCL_1624

Record Creation Time: 20220427T221359+0000

Record Last Update: 20260905T181957+0000

Ratings and Alerts

No rating or validation information has been found for ONS-76.

No alerts have been found for ONS-76.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Kubon N, et al. (2026) Detection of structural DNA variants in medulloblastomas using optical genome mapping. *Acta neuropathologica communications*, 14(1).

Wu YS, et al. (2026) 7,7"-dimethoxyagastisflavone induced MYCN/MYBL2-dependent apoptosis and metabolism reprogramming in Sonic Hedgehog medulloblastoma. *Journal of translational medicine*, 24(1).

Wang Y, et al. (2026) GPC6 facilitates progression of SHH-subgroup medulloblastoma by enhancing Hedgehog secretion and signaling responses. *Journal of biomedical research*, 40(3), 228.

Gou P, et al. (2025) The dual HDAC/PI3K inhibitor CUDC-907 inhibits the growth and proliferation of MYC-driven Group 3 medulloblastoma. *Cell death discovery*, 11(1), 172.

Dang D, et al. (2025) Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis. *Cancer cell*, 43(6), 1159.

Hofman DA, et al. (2024) Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. *Molecular cell*, 84(2), 261.

Vollmer J, et al. (2023) Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells. *Journal of neuro-oncology*, 164(3), 617.

Hofman DA, et al. (2023) Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. *bioRxiv : the preprint server for biology*.

Echavidre W, et al. (2023) Integrin- α 3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance. *Cancer research communications*, 3(12), 2483.

Rossi M, et al. (2022) Beta-blockers disrupt mitochondrial bioenergetics and increase radiotherapy efficacy independently of beta-adrenergic receptors in medulloblastoma. *EBioMedicine*, 82, 104149.

Veo B, et al. (2021) Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in MYC-driven medulloblastoma. *Cell reports*, 35(4), 109013.

Gampala S, et al. (2021) Activation of AMPK sensitizes medulloblastoma to Vismodegib and overcomes Vismodegib-resistance. *FASEB bioAdvances*, 3(6), 459.

Wei Y, et al. (2019) p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma. *Molecular cancer research : MCR*, 17(1), 186.

Xie Q, et al. (2018) N6-methyladenine DNA Modification in Glioblastoma. *Cell*, 175(5), 1228.

Klisch TJ, et al. (2017) Jak2-mediated phosphorylation of Atoh1 is critical for medulloblastoma growth. *eLife*, 6.